Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.

By C. Annunziata, R. Davis, Y. Demchenko, W. Bellamy, A. Gabrea, F. Zhan, G. Lenz, I. Hanamura, George E. Wright, Wenming Xiao and 12 more. Cancer Cell, 2007

1,021 citations recorded by the source corpus.

Subfields: Cancer Research, Hematology, Oncology

View Paper: https://www.semanticscholar.org/paper/0a530ced27dcc3e4d7e97d1634258d5487f783ec

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. A. Mantovani
2. Véronique Baud
3. A. Sica
4. Joseph A. DiDonato
5. F. Mercurio
6. T. Hirano
7. M. Karin
8. P. Allavena

In Hematology

1. T. Hirano
2. M. Karin
3. A. Mantovani
4. C. Garlanda

In Oncology

1. A. Mantovani
2. M. Karin
3. A. Sica
4. P. Allavena
5. C. Garlanda
6. T. Hirano
7. F. Colotta
8. Véronique Baud

Citations in the corpus

• NF‐κB and the link between inflammation and cancer (2012, background): “Clues as to possible alternative functions for IKKa were arrived at through the notice that the aly mouse which is defective in NIK activity, the relb) ⁄ ) mouse and the IKKa) ⁄ ) mouse all suffer from defective secondary lymphoid organ development (80–83).”
• Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. (2009, background): “In multiple myeloma, a well known IL-6-dependent neoplasia, it was recently described an alternative pathway of connection between IL-6 and NF-kB [33,34].”
• IAPs: from caspase inhibitors to modulators of NF-κB, inflammation and cancer (2010, background): “For example, 20% of patients with multiple myeloma have genetic lesions that drive unrestrained non-canonicalNF-κB signallin”